Lophius Biosciences further on the course to success
Lophius Biosciences, a young biotechnology company founded through the Regensburg University Clinic, develops innovative products for the diagnosis of active infectious and autoimmune diseases. Additionally the company offers customer-specific services in the field of cell-based bioactivity and quality tests for pharmaceutical substances. The core competencies of the company lie in the field of immunology and T-cell diagnostics. T cells are an important group of white blood cells and are part of the body’s defence system. In summer Lophius was one of the few biotech companies in Germany to successfully seal a round of financing of over 1.6 million €. Recently the company announced the important grant of a patent for a further basic patent in the USA. This patent already granted in Europe represents an essential building block for Lophius Biosciences with respect to T cell based technology platforms and permits the development of diagnostics, which for the first time allows comprehensive in vitro assessment of the cellular immune functions occurring in the body. Furthermore this opens an opportunity for the development of novel adjuvant-free vaccines with an improved spectrum of efficacy. The successful company is planning its expansion for 2011 in the third section of the building currently under construction.
For more information see: